Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

Results

Save Results

For more information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.

Clinical Trial	Phase	Eligible Participant	Official Title	Drugs in Trial	Location
NCT02855944	III	Recurrent or progressive high grade serous or endometrioid ovarian cancer with BRCA1/2 mutations (>1 prior therapy)	ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	View Drugs	Colorado, Georgia
Drug(s) in Trial Other Drug Names Main Known Action Rucaparib AG-014699, PF 01367338, CO-338, Rubraca PARP inhibitor
NCT03398655	III	Platinum resistant ovarian cancer	A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer	View Drugs	Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kansas, Kentucky, Louisiana, Maryland, Massachusetts, Michigan, Montana, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, South Carolina, Tennessee, Texas, Vermont, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action Ofranergene Obadenovec VB-111 Endothelin promoter-apoptotic receptor gene therapy Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor
NCT02584478	IIa	Recurrent ovarian cancer	A Phase 1/2a Evaluation of the Safety and Efficacy of Adding AL3818, a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy, in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)	View Drugs	California, Florida, Louisiana, Texas
Drug(s) in Trial Other Drug Names Main Known Action Anlotinib AL3818 VEGFR2/3 kinase inhibitor Carboplatin Paraplatin, Novoplatinum DNA damaging agent Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor
NCT02419417	IIa	Platinum resistant or refractory ovarian cancer with BRCA1/2 mutations	A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, as Monotherapy or in Combination With Nivolumab in Subjects With Selected Advanced Solid Tumors or Hematologic Malignancies	View Drugs	California, Colorado, Massachusetts, Oregon, Pennsylvania, South Carolina
Drug(s) in Trial Other Drug Names Main Known Action BMS-986158 BET inhibitor BMS-986158 BET inhibitor Nivolumab BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo Blocks PD-L1/2 inhibition of T cells
NCT02091141	IIa	Advanced solid tumors with ALK mutations or high TMB	My Pathway: An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents	View Drugs	Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Maryland, Minnesota, Missouri, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, South Dakota, Tennessee, Texas, Washington, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action Alectinib ALK inhibitor CH5424802, Alecensa, anaplastic lymphoma kinase inhibitor CH5424802, AF802 ALK kinase inhibitor Atezolizumab Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 Blocks PD-L1 inhibition of T cells
NCT02502266	II/III	Platinum resistant or refractory high grade serous or endometrioid ovarian cancer or germline BRCA1/2-mutated ovarian cancer	A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)	View Drugs	Alabama, Alaska, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action Cediranib AZD2171, Cediranib maleate, Recentin VEGFR1-3 kinase inhibitor Olaparib AZD2281, Lynparza PARP inhibitor
NCT01037790	II	Advanced solid tumors with CCND1/2 amplification, CDK4/6 mutation, or other G1/S alterations	Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer	View Drugs	Pennsylvania
Drug(s) in Trial Other Drug Names Main Known Action Palbociclib PD-0332991, PD0332991, Ibrance CDK4/6 inhibitor
NCT01953926	II	Advanced solid tumors with activating HER2 mutations	An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification.	View Drugs	Alabama, Arizona, California, Delaware, Florida, Georgia, Illinois, Louisiana, Massachusetts, Minnesota, Missouri, New York, Ohio, Pennsylvania, South Carolina, Tennessee, Texas, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action Neratinib HKI-272, PD272 EGFR, HER2, HER4 kinase inhibitor
NCT02203513	II	Recurrent high grade serous or endometrioid or germline BRCA1/2-mutated ovarian cancer	A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) In BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, and High Grade Serous Ovarian Cancer	View Drugs	Maryland
Drug(s) in Trial Other Drug Names Main Known Action Prexasertib checkpoint kinase 1 inhibitor LY2606368, LY2606368 Chk1/2 inhibitor
NCT02312245	II	Platinum resistant or refractory ovarian cancer	Avatar-Directed Chemotherapy in Platinum-Resistant Ovarian, Primary Peritoneal and Fallopian Tube Cancers	View Drugs	Arizona, Florida, Minnesota
Drug(s) in Trial Other Drug Names Main Known Action Gemcitabine Gemzar Ribonucleotide reductase and DNA synthesis inhibitor Liposomal doxorubicin Doxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride Topoisomerase II inhibitor Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor Topotecan Hycamptamine, Hycamtin, TOPO Topoisomerase I inhibitor
NCT02272998	II	Advanced solid tumors with FGFR1-4, PDGFRa, Kit, RET, FLT3, or Abl1 alterations	Phase II Study of Ponatinib for Advanced Cancers With Genomic Alterations in Fibroblastic Growth Factor Receptor (FGFR) and Other Genomic Targets (KIT, PDGFRá, RET FLT3, ABL1)	View Drugs	Ohio
Drug(s) in Trial Other Drug Names Main Known Action Ponatinib multitargeted tyrosine kinase inhibitor AP24534, Iclusig, AP24534 Multi-targeted kinase inhibitor
NCT02079740	II	Advanced solid tumors with KRAS or NRAS mutations (in expansion)	An Open Label, Two-Part, Phase Ib/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor Trametinib and the BCL2-Family Inhibitor Navitoclax (ABT-263) in Combination in Subjects With KRAS or NRAS Mutation-Positive Advanced Solid Tumors	View Drugs	Massachusetts
Drug(s) in Trial Other Drug Names Main Known Action Navitoclax Bcl-2 Family Protein Inhibitor ABT-263, A-855071.0, ABT-263 Bcl-2, Bcl-XL, and Bcl-w inhibitor Trametinib Mekinist, MEK Inhibitor GSK1120212, JTP-74057, GSK1120212, TMT212 MEK1/2 inhibitor
NCT02571725	II	Recurrent ovarian cancer with germline BRCA1/2 mutations (no prior anti-CTLA-4 mAb)	A Phase 1-2 Study of the Combination of Olaparib and Tremelimumab, in BRCA1 and BRCA2 Mutation Carriers With Recurrent Ovarian Cancer	View Drugs	Florida, New Mexico, Ohio, Virginia
Drug(s) in Trial Other Drug Names Main Known Action Olaparib AZD2281, Lynparza PARP inhibitor Tremelimumab anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab Blocks CTLA-4 inhibition of T cells
NCT02568267	II	Advanced solid tumors with NTRK1/2/3, ROS1, or ALK rearrangements	An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements	View Drugs	Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nevada, New York, North Carolina, Ohio, Oregon, Texas, Utah, Virginia, Washington
Drug(s) in Trial Other Drug Names Main Known Action Entrectinib TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, RXDX-101 ALK, TRK, ROS1 kinase inhibitor
NCT02693535	II	Advanced solid tumors with molecular alterations in AKT1, ALK, ATM, BRAF, BRAFV600E/D/K/R, BRCA1/2, CDK4, CDK6, CDKN2A, CSF1R, ERBB2, FGFR1-3, FLT-3, KIT, MET, MLH1, MSH2, MSH6, mTOR, PALB2, PDGFR, PDGFRB, PMS2, POLD1, POLE, RAF-1, RET, ROS1, TSC1/2, VEGFR, high MSI, high TMB	Targeted Agent and Profiling Utilization Registry (TAPUR) Study	View Drugs	Alabama, Arizona, California, Florida, Georgia, Hawaii, Illinois, Indiana, Massachusetts, Michigan, Nebraska, North Carolina, North Dakota, Oklahoma, Oregon, Pennsylvania, South Dakota, Texas, Utah, Virginia, Washington
Drug(s) in Trial Other Drug Names Main Known Action Abemaciclib Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio CDK4/6 inhibitor Afatinib BIBW 2992 MA2, Gilotrif, Afatinib dimaleate EGFR, HER2, HER4 kinase inhibitor Cobimetinib XL518, GDC-0973, Cotellic MEK1 inhibitor Crizotinib c-met/HGFR tyrosine kinase inhibitor PF-02341066, PF-02341066, Xalkori c-Met and ALK kinase inhibitor Ipilimumab Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy Blocks CTLA-4 inhibition of T cells Nivolumab BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo Blocks PD-L1/2 inhibition of T cells Olaparib AZD2281, Lynparza PARP inhibitor Palbociclib PD-0332991, PD0332991, Ibrance CDK4/6 inhibitor Pembrolizumab Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 Blocks PD-L1/2 inhibition of T cells Pertuzumab Perjeta, monoclonal antibody 2C4, rhuMAb2C4 HER2 dimerization inhibitor Regorafanib BAY73-4506, multikinase inhibitor BAY 73-4506, Stivarga Multi-targeted RTK inhibitor Sunitinib Sutent, Sunitinib malate VEGFR2, PDGFR-beta, c-Kit, and FLT3 kinase inhibit Talazoparib Talazoparib Tosylate, BMN-673, MDV3800 PARP inhibitor Temsirolimus Torisel, CCI-779 mTOR inhibitor Trastuzumab Herceptin, Anti-erbB2 Monoclonal Antibody, HER2 Monoclonal Antibody HER2 antagonist Vemurafenib RO5185426, PLX4032, Zelboraf BRAF kinase inhibitor
NCT02465060	II	Advanced solid tumors with alterations in AKT, BRAF, cKIT, CDK4 AMP, CDK6 AMP, EGFR, ERBB2 AMP, FGFR1-4, FGFR1-4 AMP, MET, MET AMP, mTOR, NTRK1-3, PIK3CA, PTCH1, PTEN, SMO, TSC1/2	Molecular Analysis for Therapy Choice (MATCH)	View Drugs	Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming
Drug(s) in Trial Other Drug Names Main Known Action Afatinib BIBW 2992 MA2, Gilotrif, Afatinib dimaleate EGFR, HER2, HER4 kinase inhibitor Copanlisib BAY 80-6946, MEK inhibitor BAY 80-6946, PI3K inhibitor BAY 80-6946 pan-PI3K inhibitor Crizotinib c-met/HGFR tyrosine kinase inhibitor PF-02341066, PF-02341066, Xalkori c-Met and ALK kinase inhibitor Erdafitinib pan-FGFR tyrosine kinase inhibitor JNJ-42756493 pan-FGFR kinase inhibitor Ipatasertib GDC-0068, Akt Inhibitor GDC-0068, RG7440 pan-AKT inhibitor Larotrectinib Trk inhibitor LOXO-101 pan-Trk kinase inhibitor Osimertinib Tagrisso, AZD9291, EGFR inhibitor AZD9291, Mereletinib EGFR kinase inhibitor Palbociclib PD-0332991, PD0332991, Ibrance CDK4/6 inhibitor Pertuzumab Perjeta, monoclonal antibody 2C4, rhuMAb2C4 HER2 dimerization inhibitor Sapanisertib INK128, TORC1/2 Inhibitor INK128, TORC1/2 Inhibitor MLN0128, MLN0128, TAK-228 TORC1/2 kinase inhibitor Sunitinib Sutent, Sunitinib malate VEGFR2, PDGFR-beta, c-Kit, and FLT3 kinase inhibit Trastuzumab Herceptin, Anti-erbB2 Monoclonal Antibody, HER2 Monoclonal Antibody HER2 antagonist Trastuzumab emtansine trastuzumab-MCC-DM1 immunoconjugate, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1, trastuzumab-DM1, T-DM1, Kadcyla, ado trastuzumab emtansine ADC: anti-HER2 + microtubule destabilizer (DM1) Ulixertinib BVD-523, ERK inhibitor BVD-523 ERK inhibitor Vismodegib Hedgehog antagonist GDC-0449, Erivedge, GDC-0449 Smoothened antagonist
NCT02628067	II	Advanced solid tumors with high MSI	A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)	View Drugs	California, Colorado, Florida, Maryland, Massachusetts, New Jersey, New Mexico, Texas
Drug(s) in Trial Other Drug Names Main Known Action Pembrolizumab Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 Blocks PD-L1/2 inhibition of T cells
NCT02576444	II	Advanced solid tumors with AKT, ARID1A, ATM, CDKN2A, CHEK2, IDH1/2, KRAS, MRE11A, PIK3CA, PTEN, TP53 and other HDR gene mutations	A Phase II Study of the PARP Inhibitor Olaparib (AZD2281) Alone and in Combination With AZD1775, AZD5363, or AZD6738 in Advanced Solid Tumors	View Drugs	Connecticut, Massachusetts, Ohio, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action Adavosertib WEE1 inhibitor AZD1775, MK1775, AZD1775 WEE1 inhibitor Capivasertib Akt inhibitor AZD5363 pan-AKT inhibitor Ceralasertib AZD6738, ATR kinase inhibitor AZD6738 ATR kinase inhibitor Olaparib AZD2281, Lynparza PARP inhibitor
NCT02554812	II	Advanced solid tumors (in ovarian expansion)	A Phase 1b/2 Open-Label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (MSB0010718C) In Combination With Other Cancer Immunotherapies In Patients With Advanced Malignancies	View Drugs	California, District of Columbia, Florida, Iowa, Michigan, New York, North Carolina, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Washington
Drug(s) in Trial Other Drug Names Main Known Action Avelumab Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio Blocks PD-L1 inhibition of T cells PD-0360324 anti–M-CSF mAb PD-0360324, anti-CSF1 monoclonal antibody PD-0360324 CSF1R antagonist and tumor-associated macrophage inhibitor PF-04518600 anti-OX40 antibody PF-04518600 Stimulates OX40 to increase T cell activation and immune response
NCT02832167	II	Advanced solid tumors	An Open Label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies	View Drugs	Arizona, California, Colorado, Florida, Illinois, Indiana, Maryland, Minnesota, Missouri, Nebraska, Nevada, New Jersey, New York, Oregon, South Carolina, Tennessee, Texas, Virginia
Drug(s) in Trial Other Drug Names Main Known Action Nivolumab BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo Blocks PD-L1/2 inhibition of T cells
NCT01827384	II	Advanced solid tumors with mutations in BRAF, KRAS, NRAS, NF1, PIK3CA, AKT1, MTOR, FBXW7, PTEN, ATM, ATR, ERCC1, MLH1, MSH2, NBN, RAD51, PARP1/2,TP53	Molecular Profiling-Based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors	View Drugs	Colorado, Georgia, Kentucky, Maryland, Missouri, New Jersey, Pennsylvania, Texas
Drug(s) in Trial Other Drug Names Main Known Action Adavosertib WEE1 inhibitor AZD1775, MK1775, AZD1775 WEE1 inhibitor Carboplatin Paraplatin, Novoplatinum DNA damaging agent Everolimus Afinitor, Certican, RAD001, Zortress mTOR inhibitor Temozolomide Temodal, Temodar, Methazolastone DNA damaging agent Trametinib Mekinist, MEK Inhibitor GSK1120212, JTP-74057, GSK1120212, TMT212 MEK1/2 inhibitor Veliparib ABT-888 PARP inhibitor
NCT02873962	II	Platinum resistant or partially sensitive ovarian cancer	A Phase II Study With a Safety lead-in of Nivolumab in Combination With Bevacizumab or in Combination With Bevacizumab and Rucaparib for the Treatment of Relapsed Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer	View Drugs	Massachusetts
Drug(s) in Trial Other Drug Names Main Known Action Bevacizumab immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin VEGF antagonist Nivolumab BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo Blocks PD-L1/2 inhibition of T cells Rucaparib AG-014699, PF 01367338, CO-338, Rubraca PARP inhibitor
NCT02873975	II	Advanced solid tumors with MYC or CCNE1 amplification, Rb loss, or FBXW7, BRCA1, BRCA2, PALB2, RAD51C, RAD51D, ATR, ATM, CHEK2, Fanconi anemia pathway mutations	A Phase II Study of the CHK1 Inhibitor LY2606368 in Patients With Advanced Solid Tumors Exhibiting Replicative Stress or Homologous Recombination Repair Deficiency	View Drugs	Massachusetts
Drug(s) in Trial Other Drug Names Main Known Action Prexasertib checkpoint kinase 1 inhibitor LY2606368, LY2606368 Chk1/2 inhibitor
NCT01851369	II	Advanced solid tumors and granulosa cell ovarian cancer (in expansion)	A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and Lymphomas	View Drugs	Maryland
Drug(s) in Trial Other Drug Names Main Known Action Methoxyamine TRC102 Base excision repair inhibitor Temozolomide Temodal, Temodar, Methazolastone DNA damaging agent
NCT02901899	II	Platinum resistant ovarian cancer	An Open Label Phase II Trial of Guadecitabine and Pembrolizumab in Platinum Resistant Recurrent Ovarian Cancer	View Drugs	Illinois
Drug(s) in Trial Other Drug Names Main Known Action Guadecitabine DNA methyltransferase inhibitor SGI-110, SGI-110 DNA methylation inhibitor Pembrolizumab Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 Blocks PD-L1/2 inhibition of T cells
NCT02364713	II	Platinum resistant, refractory or persistent ovarian cancer (disease outside the peritoneal cavity)	A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer	View Drugs	Arizona, Florida, Minnesota
Drug